Targeting the Tumor Stroma as a Novel Treatment Strategy for Breast Cancer. Shifting from the Neoplastic Cell-Centric to a Stroma-Centric Paradigm

Advances in Pharmacology

Volumn 65, Issue , 2012, Pages 45-61

  Tchou, Julia ^a,b   Conejo Garcia, Jose ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c WISTAR INSTITUTE   (United States)

Author keywords

Cancer associated fibroblasts; Targeted therapy; Triple negative breast cancer; Tumor microenvironment; Tumor stroma

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BEVACIZUMAB; CALVASCULIN; DNA VACCINE; DOXORUBICIN; FRESOLIMUMAB; GAMMA SECRETASE INHIBITOR; IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; R 04929097; SEPRASE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER ASSOCIATED FIBROBLAST; CANCER IMMUNIZATION; CANCER INVASION; DRUG TARGETING; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; TRIPLE NEGATIVE BREAST CANCER; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UTERINE CERVIX CANCER;

EID: 84865846037     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-397927-8.00003-8     Document Type: Chapter

References (64)

1. Abramsson A., Lindblom P., Betsholtz C. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. Journal of Clinical Investigation 2003, 112(8):1142-1151.
2. ACS cancer facts and figures. (2011). (). http://www.cancer.org.
3. Aertgeerts K., Levin I., Shi L., Snell G.P., Jennings A., Prasad G.S., et al. Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha. Journal of Biological Chemistry 2005, 280(20):19441-19444.
4. Aggarwal S., Brennen W.N., Kole T.P., Schneider E., Topaloglu O., Yates M., et al. Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites. Biochemistry 2008, 47(3):1076-1086.
5. Allinen M., Beroukhim R., Cai L., Brennan C., Lahti-Domenici J., Huang H., et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004, 6(1):17-32.
6. Baglole C.J., Reddy S.Y., Pollock S.J., Feldon S.E., Sime P.J., Smith T.J., et al. Isolation and phenotypic characterization of lung fibroblasts. Methods in Molecular Medicine 2005, 117:115-127.
7. Beatty G.L., Chiorean E.G., Fishman M.P., Saboury B., Teitelbaum U.R., Sun W., et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 331(6024):1612-1616.
8. Bhowmick N.A., Chytil A., Plieth D., Gorska A.E., Dumont N., Shappell S., et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004, 303(5659):848-851.
9. Camps J.L., Chang S.M., Hsu T.C., Freeman M.R., Hong S.J., Zhau H.E., et al. Fibroblast-mediated acceleration of human epithelial tumor growth in vivo. Proceedings of the National Academy of Sciences U S A 1990, 87(1):75-79.
10. Carey L.A., Perou C.M., Livasy C.A., Dressler L.G., Cowan D., Conway K., et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. Jama 2006, 295(21):2492-2502.
11. Chang H.Y., Chi J.T., Dudoit S., Bondre C., van de Rijn M., Botstein D., et al. Diversity, topographic differentiation, and positional memory in human fibroblasts. Proceedings of the National Academy of Sciences U S A 2002, 99(20):12877-12882.
12. Clementz A.G., Rogowski A., Pandya K., Miele L., Osipo C. NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications. Breast Cancer Research 2011, 13(3):R63.
13. Comoglio P.M., Trusolino L. Cancer: the matrix is now in control. Nature Medicine 2005, 11(11):1156-1159.
14. Cristofanilli M., Morandi P., Krishnamurthy S., Reuben J.M., Lee B.N., Francis D., et al. Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations. Annals of Oncology 2008, 19(10):1713-1719.
15. Cubillos-Ruiz J.R., Martinez D., Scarlett U.K., Rutkowski M.R., Nesbeth Y.C., Camposeco-Jacobs A.L., et al. CD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells. Oncotarget 2010, 1(5):329-338.
16. Dent R., Trudeau M., Pritchard K.I., Hanna W.M., Kahn H.K., Sawka C.A., et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clinical Cancer Research 2007, 13(15 Pt 1):4429-4434.
17. Edosada C.Y., Quan C., Tran T., Pham V., Wiesmann C., Fairbrother W., et al. Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly(2)-Pro(1)-cleaving specificity. FEBS Letters 2006, 580(6):1581-1586.
18. Egeblad M., Littlepage L.E., Werb Z. The fibroblastic coconspirator in cancer progression. Cold Spring Harbor Symposia on Quantitative Biology 2005, 70:383-388.
19. Finak G., Bertos N., Pepin F., Sadekova S., Souleimanova M., Zhao H., et al. Stromal gene expression predicts clinical outcome in breast cancer. Nature Medicine 2008, 14(5):518-527.
20. Gaggioli C., Hooper S., Hidalgo-Carcedo C., Grosse R., Marshall J.F., Harrington K., et al. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nature Cell Biology 2007, 9(12):1392-1400.
21. Garin-Chesa P., Old L.J., Rettig W.J. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proceedings of the National Academy of Sciences U S A 1990, 87(18):7235-7239.
22. Gleave M., Hsieh J.T., Gao C.A., von Eschenbach A.C., Chung L.W. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Research 1991, 51(14):3753-3761.
23. Grum-Schwensen B., Klingelhofer J., Grigorian M., Almholt K., Nielsen B.S., Lukanidin E., et al. Lung metastasis fails in MMTV-PyMT oncomice lacking S100A4 due to a T-cell deficiency in primary tumors. Cancer Research 2010, 70(3):936-947.
24. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
25. Hayward S.W., Wang Y., Cao M., Hom Y.K., Zhang B., Grossfeld G.D., et al. Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Research 2001, 61(22):8135-8142.
26. Hu M., Polyak K. Microenvironmental regulation of cancer development. Current Opinion in Genetics & Development 2008, 18(1):27-34.
27. Kakkad S.M., Solaiyappan M., O'Rourke B., Stasinopoulos I., Ackerstaff E., Raman V., et al. Hypoxic tumor microenvironments reduce collagen I fiber density. Neoplasia 2010, 12(8):608-617.
28. Kelly T. Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy. Drug Resistance Updates 2005, 8(1-2):51-58.
29. Kraman M., Bambrough P.J., Arnold J.N., Roberts E.W., Magiera L., Jones J.O., et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 2010, 330(6005):827-830.
30. Larsen M., Artym V.V., Green J.A., Yamada K.M. The matrix reorganized: extracellular matrix remodeling and integrin signaling. Current Opinion in Cell Biology 2006, 18(5):463-471.
31. Lenzer J. FDA committee votes to withdraw bevacizumab for breast cancer. BMJ 2011, 343:d4244.
32. Levental K.R., Yu H., Kass L., Lakins J.N., Egeblad M., Erler J.T., et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139(5):891-906.
33. Liao D., Luo Y., Markowitz D., Xiang R., Reisfeld R.A. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One 2009, 4(11):e7965.
34. Liotta L.A., Kohn E.C. The microenvironment of the tumour-host interface. Nature 2001, 411(6835):375-379.
35. Martin D.N., Boersma B.J., Yi M., Reimers M., Howe T.M., Yfantis H.G., et al. Differences in the tumor microenvironment between African-American and European-American breast cancer patients. PLoS One 2009, 4(2):e4531.
36. Nadiarnykh O., LaComb R.B., Brewer M.A., Campagnola P.J. Alterations of the extracellular matrix in ovarian cancer studied by Second Harmonic Generation imaging microscopy. BMC Cancer 2010, 10:94.
37. Narra K., Mullins S.R., Lee H.O., Strzemkowski-Brun B., Magalong K., Christiansen V.J., et al. Phase II trial of single agent Val-boroPro (Talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer. Cancer Biology & Therapy 2007, 6(11):1691-1699.
38. Neesse A., Michl P., Frese K.K., Feig C., Cook N., Jacobetz M.A., et al. Stromal biology and therapy in pancreatic cancer. Gut 2011, 60(6):861-868.
39. Noma K., Smalley K.S., Lioni M., Naomoto Y., Tanaka N., El-Deiry W., et al. The essential role of fibroblasts in esophageal squamous cell carcinoma-induced angiogenesis. Gastroenterology 2008, 134(7):1981-1993.
40. Olumi A.F., Grossfeld G.D., Hayward S.W., Carroll P.R., Tlsty T.D., Cunha G.R. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Research 1999, 59(19):5002-5011.
41. Orimo A., Gupta P.B., Sgroi D.C., Arenzana-Seisdedos F., Delaunay T., Naeem R., et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121(3):335-348.
42. Orimo A., Weinberg R.A. Heterogeneity of stromal fibroblasts in tumors. Cancer Biology & Therapy 2007, 6(4):618-619.
43. Pardoll D., Drake C. Immunotherapy earns its spot in the ranks of cancer therapy. Journal of Experimental Medicine 2012, 209(2):201-209.
44. Park J.E., Lenter M.C., Zimmermann R.N., Garin-Chesa P., Old L.J., Rettig W.J. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. Journal of Biological Chemistry 1999, 274(51):36505-36512.
45. Paszek M.J., Zahir N., Johnson K.R., Lakins J.N., Rozenberg G.I., Gefen A., et al. Tensional homeostasis and the malignant phenotype. Cancer Cell 2005, 8(3):241-254.
46. Petersen O., Ronnov-Jessen L., Howlett A., Bissell M. Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. PNAS 1992, 89(19):9064-9068.
47. Picard O., Rolland Y., Poupon M.F. Fibroblast-dependent tumorigenicity of cells in nude mice: implication for implantation of metastases. Cancer Research 1986, 46(7):3290-3294.
48. Pietras K., Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Experimental Cell Research 2010, 316(8):1324-1331.
49. Pietras K., Pahler J., Bergers G., Hanahan D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Medicine 2008, 5(1):e19.
50. Presta L.G., Chen H., O'Connor S.J., Chisholm V., Meng Y.G., Krummen L., et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Research 1997, 57(20):4593-4599.
51. Provenzano P.P., Inman D.R., Eliceiri K.W., Keely P.J. Matrix density-induced mechanoregulation of breast cell phenotype, signaling and gene expression through a FAK-ERK linkage. Oncogene 2009, 28(49):4326-4343.
52. Provenzano P.P., Inman D.R., Eliceiri K.W., Knittel J.G., Yan L., Rueden C.T., et al. Collagen density promotes mammary tumor initiation and progression. BMC Medicine 2008, 6:11.
53. Rehman A.O., Wang C.Y. Notch signaling in the regulation of tumor angiogenesis. Trends in Cell Biology 2006, 16(6):293-300.
54. Rettig W.J., Garin-Chesa P., Healey J.H., Su S.L., Ozer H.L., Schwab M., et al. Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Research 1993, 53(14):3327-3335.
55. Santos A.M., Jung J., Aziz N., Kissil J.L., Pure E. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. Journal of Clinical Investigation 2009, 119(12):3613-3625.
56. Shao H., Cai L., Grichnik J.M., Livingstone A.S., Velazquez O.C., Liu Z.J. Activation of Notch1 signaling in stromal fibroblasts inhibits melanoma growth by upregulating WISP-1. Oncogene 2011, 30(42):4316-4326.
57. Smith I.A., Knezevic B.R., Ammann J.U., Rhodes D.A., Aw D., Palmer D.B., et al. BTN1A1, the mammary gland butyrophilin, and BTN2A2 are both inhibitors of T cell activation. Journal of Immunology 2010, 184(7):3514-3525.
58. Steg A.D., Katre A.A., Goodman B., Han H.D., Nick A.M., Stone R.L., et al. Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer. Clinical Cancer Research 2011, 17(17):5674-5685.
59. Sugimoto H., Mundel T.M., Kieran M.W., Kalluri R. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biology & Therapy 2006, 5(12):1640-1646.
60. Tarabykina S., Griffiths T.R., Tulchinsky E., Mellon J.K., Bronstein I.B., Kriajevska M. Metastasis-associated protein S100A4: spotlight on its role in cell migration. Current Cancer Drug Targets 2007, 7(3):217-228.
61. Tlsty T. Cancer: whispering sweet somethings. Nature 2008, 453(7195):604-605.
62. Weaver V.M., Petersen O.W., Wang F., Larabell C.A., Briand P., Damsky C., et al. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. Journal of Cell Biology 1997, 137(1):231-245. doi:10.1083/jcb.137.1.231.
63. Yardley D.A., Burris H.A., Markus T., Spigel D.R., Greco F.A., Mainwaring M., et al. Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer. Clinical Breast Cancer 2009, 9(4):237-242.
64. Zitvogel L., Kepp O., Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nature Reviews Clinical Oncology 2011, 8(3):151-160.